---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-206395"
form_type: "8-K"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:13:44.324764+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools Q1 revenue $21.1M, up 5% YoY; operating loss cut 54%

## Summary
- Net loss from continuing ops $14.6M vs $23.4M YoY; adjusted EBITDA loss $3.1M, 78% improvement.
- Revenue $21.1M (+5% YoY); consumables up 35% to $11.0M, instruments down 33% to $4.5M.
- Cash & investments $524M at quarter end, plus $25M earnout received post-Q1; total ~$550M.
- Full-year 2026 revenue outlook unchanged at $80M-$85M; path to positive adjusted EBITDA exiting 2026.
- Operating expenses down 37% to $23.8M, helped by restructuring; non-GAAP gross margin 57.7%.

## SEC filing metadata
- accession: 0001193125-26-206395
- form_type: 8-K
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000119312526206395/0001193125-26-206395-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000119312526206395/lab-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-206395
- JSON: https://secwatch.observer/filing/0001193125-26-206395.json
- Plain text: https://secwatch.observer/filing/0001193125-26-206395.txt

## Source-grounded claims
- claim_id: 801483aeb1af9dc724a5ff23148dc8da3526beda
  claim: STANDARD BIOTOOLS INC. reported the quarter ended March 31, 2026 results: revenue $21.1 million, net income $14.6 million. Guidance reaffirmed.
  evidence_excerpt: (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended March 31, 2026. Recent Highlights: • First quarter 2026 revenue of $21.1 million • 54% reduction in operating loss and 78% improvement in adjusted EBITDA year-over-year supporting path to positive adjusted EBITDA exiting 2026 • $524 million in cash &
  evidence_url: https://www.sec.gov/Archives/edgar/data/1162194/000119312526206395/0001193125-26-206395-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.